Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...

--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Holdings Inc. ("illumin" or "Company"), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, announces that it will ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

This was primarily driven by the launch of Livdelzi® (seladelpar) in primary biliary cholangitis ("PBC"), and increased demand in products for chronic hepatitis B virus ("HBV") and chronic hepatitis ...

Ingram Micro Inc. , a business-to-business (B2B) platform company for the global technology ecosystem, today announced its two partner communities?Ingram Micro SMB Alliance and Ingram Micro Trust X ...